JMSCR Vol 3 Issue 10 Page October 2015
|
|
- Rudolf Tate
- 5 years ago
- Views:
Transcription
1 Impact Factor 3.79 ISSN (e) x DOI: Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral Therapy Authors Deebii, N 1*, Orluwene, CG 2, Korubo, K. I 1, and Njoku, B 3 1 Department of Haematology, Blood Transfusion and Immunology, University of Port Harcourt, Rivers State, Nigeria 2 Department of Chemical Pathology, University of Port Harcourt, Rivers State, Nigeria 3 Department of Human Physiology, Faculty of Basic Medical Sciences, University of Port Harcourt, Rivers State, Nigeria * Corresponding Author Numbara Deebii Department of Haematology, Blood Transfusion and Immunology, University of Port Harcourt, Rivers State, Nigeria numbarakomene@yahoo.com, Abstract The present study examines the effects of antiretroviral therapy (ART) on two basic immunohaematological parameters over time. We performed a retrospective study of HIV-infected treatment-naïve patients starting a first line ART between June 2014 and January 2015, and followed-up for 12 weeks. On the whole, 254HIV-infected treatment naive patients were enrolled: 100 patients on tenoforvir (TDF) based regimen was compared with 102 and 52 non-tdf based regimen and treatment-naïve patients respectively. Samples were collected at three different points (at baseline, 4 weeks and 12 weeks).cd4 and haemoglobin (Hb) were found to be significantly higher (p=0.001) in the TDF group as compared to non-tdf groups after 12 weeks of follow-up, although there was no significant difference between the Non-TDF group and ART-naive group at 4 and 12 weeks in both parameters. These results demonstrate that the initiation of a TDF based-regimen is followed by an increase in lymphocyte proliferation and lymphocyte-mediated cytotoxicity compared to other non-tdf based-regimen group. However we suggest that TDF should be part of an antiretroviral regimen in immunosuppressed patients at risk of anaemia. Keywords: HIV, Tenoforvir (TDF), CD4 and immunosuppressed INTRODUCTION Several longitudinal studies have described infection with human immunedeficiency virus (HIV) causes a progressive dysfunction of the immune system in which there is reduced number of circulating CD4 T cells 1 which is preceded by increased levels of circulating HIV RNA. This predicts disease progression, with development of acquired immune deficiency syndrome (AIDS) and death in the absence of therapy. The CD4 count is the most important laboratory indicator of immune function in HIV-infected patients. It also Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7828
2 the strongest predictor of subsequent used to assess immunity, disease progression and survival according to findings from clinical trials and cohort studies.2. Thus CD4 is used to assess a patient s immunologic response to antiretroviral therapy. CD4 count response to ART varies widely but a poor CD4 response in patients with viral suppression is rarely an indication for modifying an ARV regimen. Low Heamoglobin (Hb) also characterizes the malfunction of the immune system in HIV infection and has been suggested as additional predictive markers of HIV disease progression. 3.New treatment strategies, including the use of effective HIV-specific protease inhibitors such as tenofovir (TDF) or lavimidine, have swept the scientific community withhope caused by dramatic reductions of viral load and similar increases of CD4 cell counts. 4. Similarly the use of protease inhibitors and triple therapy in clinical practice has been associated with a marked lowering of HIV-related morbidity. 5. However, clinical reports of severe opportunistic infections in the presence of satisfactory responses to antiretroviral treatment as evaluated by increases in CD4 cell counts 6, have suggested that an increase in CD4 cell count may not always be accompanied by a similar augmentation of the functional capacity of the immune system, or that specific immune defects may persist despite treatment-induced reconstitution of other parts of the immune system. MATERIALS AND METHOD Study population A longitudinal study of 254 HIV-infected naive patients was started between June 2014 and January 2015 at the HIV clinic of the University of Port Harcourt teaching hospital, a reference hospital for tropical infection and disease located in Port Harcourt, Nigeria. HIV-infected Naïve Patients never exposed to ART were invited to participate in the study so far they can be allocated in to any of the three groups; patients to be place on TDF regimen, patients to be place on Non-TDF regimen and HIV-infected patients that will not be exposed to antiretroviral therapy during the study period. From every patient s social-demographics details of age, sex, occupation, education, income, and HIV status (CD4 T-lymphocyte count) were recorded at the time of recruitment in to the study. Samples were collected at three times point (at baseline, after 4 weeks and after 12 weeks of follow-up). Periods of drug interruption for any reason, if occurring, were discounted. Treatment was provided without any cost to patients. Statistical analysis Continuous values are given as mean and standard deviation while categorical data are given as percentages. The three groups of patients analyzed were first compared using chi-squared for categorical data and pair tests for continuous variables. The level of significance was All statistical analyses were performed using SPSS version 20.0 software package (SPSS Inc., Chicago, Illinois, USA). RESULTS A total of two hundred and sixty seven patients were recruited in to the study from June 2014 to January Complete data were obtained from 254 patients while 13 patients were lost to followup. Of the 254 patients, 202 patients started a first line antiretroviral therapy (100 Patients on TDF and 102 patients on Non-TDF Antiretroviral therapy) and during the study period all patients met inclusion and exclusion criteria. Among these 202 enrolled patients, 100 (39.37%) initiated tenofovir-containing regimen, 102 (40.16%) initiated tenofovir-sparing regimens and 52 (20.47%) antiretroviral Naïve patients. Baseline demographic characteristics and laboratory features were compared among the groups. Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7829
3 Table 1: Age and Sex Characteristics of the study population Mean Age No. of patient Std. Deviation P-Value SEX Male (33.46%) 7.69 Female (66.54%) 7.97 (Z-test ) p = Total (100%) 8.01 group TDF (39.37%) 7.68 N-TDF (40.16%) 8.68 (ANOVA) p = D-NAIVE (20.47%) 6.93 Total (100%) 8.02 Values in parenthesis showed the percentage of patients in the study population Characteristic of patients The mean age of the male and female patients were; (33.46%) and, (66.54%) years respectively with a statistically significant difference of P = The minimum and maximum age of the study population of the male and female patients were; 50:20, and 48:18 years respectively. Figure 1 shows that at baseline there was a statistically significant different between the CD4 of the treatment-naïve group and the CD4 of the TDF and Non-TDF groups (p=0.000 and respectively). After 4 weeks of follow-up, there was an increase in the CD4 of the drug treatment groups but when compared with the treatment Naïve group, the different was highly statistically significant (p=0.000 and respectively) (Figure 2). After 12 weeks of exposure and follow there was a significant increase in the TDF group as compared with the treatment Naïve and Non-TDF groups. Although there was no statistically significant different between the TDF group and the Non-TDF group, a significant different was observed between the TDF and the treatment Naïve group (p=0.04) (Figure 3). **: Significant at p=0.00 and 0.00when CD4at baseline for naïve was compared with CD4 at baseline for Non-TDF and TDF respectively Figure 1: CD4 of the study population at baseline Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7830
4 Mean CD4 (ul/cellsle) Mean CD4 (ul/cellsle 600,00 500,00 ** Mean values of CD4 for different regimen after 4 weeks 400,00 300,00 200,00 100,00 0,00 CD4 after 4 wks for Naïve CD4 after 4 wks for Non-TDF CD4 after 4 wks for TDF **: Significant at p=0.00 and 0.00when CD4after 4 wks for naïve was compared with CD4 after 4 wks for Non- TDF and TDF respectively Figure 2: CD4 of the study population after 12 weeks of exposure Mean values of CD4 for different regimen after 12 weeks 410,00 400,00 * 390,00 380,00 370,00 360,00 350,00 340,00 330,00 320,00 CD4 after 12 wks for Naïve CD4 after 12 wks for Non- TDF CD4 after 12 wks for TDF *: Significant at p=0.04 when CD4after 12 wks for TDF was compared with CD4 after 12 wks for naïve. Figure 3: CD4 of the study population after 12 weeks of exposure Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7831
5 Mean Hb (g/dl) Mean values of Hb for different regimen at baseline 13,00 12,50 ** 12,00 11,50 11,00 10,50 10,00 9,50 Hb at baseline for Naïve Hb at baseline for Non-TDF Hb at baseline for TDF **: Significant at p=0.038 and 0.016when Hbat baseline for naïve was compared with Hb at baseline for Non-TDF and TDF respectively Figure 4: Hb of the study population at baseline 13,00 Mean values of Hb for different regimen after 4 wks 12,50 ** 12,00 11,50 11,00 10,50 10,00 Hb after 4 wks for Naïve Hb after 4 wks for Non-TDF Hb after 4 wks for TDF ART regimen **: Significant at p=0.005 and 0.008when Hb after 4 wks for naïve was compared with Hb after 4 wks for Non-TDF and TDF respectively Figure 5: Hb of the study population after 4 weeks of exposure Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7832
6 Mean Hb (g/dl Mean values of Hb for different regimen after 12 wks 16,00 14,00 12,00 10,00 8,00 6,00 4,00 2,00 0,00 Hb after 12 wks for Naïve Hb after 12 wks for Non-TDF Hb after 12 wks for TDF Figure 6: Hb of the study population after 12 weeks of exposure At baseline, there was a statistical different between the haemoglobin level of the treatment Naïve group as compared to the TDF and Non- TDF groups, this different was statistically significant (p=0.031 and respectively) (Figure 4). After 4 weeks there was a noticeable increase in all the groups and the different between the treatment-naïve group and the TDF and Non-TDF groups was statistically significant (p=0.005 and respectively) (Figure 5). After 12 weeks, there was a decrease in the mean Hb values of the treatment-naïve group while there was much higher increase in the TDF group as compared with the Non-TDF group (Figure 6). DISCUSSION In this longitudinal analysis of HIV-infected patients, we found that HIV-infected patients on TDF regimen had higher CD4 and Hb values than those on Non-TDF regimen. Studies has shown that in HIV-infected patients, it is important to control the viral load at a very lower level in order to maintain a positive CD4 count slope when ART continues at later stages of the infection, particularly from 3 months to more than 24 months after ART initiation. 7. This study agree with other findings 8, that HIVinfected patients have an initially delayed CD4 count recovery at 4 weeks after HAART initiation, but at 12 weeks, CD4 count increases tramendiously. This study examines the trend of CD4 count rather than the absolute CD4 count since ART initiation decreases CD4 count. We notice in particular that there is a progressive increased in CD4 of the TDF group after 12 weeks as compared to tenofovir sparing regimen groups (Non-TDF and treatment-naive). This finding is in consistent with other reports TDF have been shown to boast the immune system in a non-specific way although a growing number of case reports and cohort studies have described an association between treatment with tenofovir and renal tubulopathy or impaired glomerular filtration rate (GFR) in patients with human immunodeficiency virus (HIV) infection Haemoglobin level increased markedly in our series of patients especially after 4 weeks of exposure to antiretroviral therapy and in treatment Naïve patients while haemoglobin is increased markedly in the two drug treatment groups and decrease in the treatment Naïve group after 12 weeks of exposure. From our result it could be believe that tenofovir could be used in the treatment of HIV-infected Patients at risk of severe anemia as compared to the other antiretroviral therapy. Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7833
7 CONCLUSION Detecting the changes in CD4 and Hb for different treatment regimen is important in the HIVinfected population given its association with increased mortality risk and potential impact on treatment choices. In this longitudinal study of HIV-infected Naïve patients, TDF appeared more sensitive in detecting and boasting the immune system and causing lymphocyte proliferation than other antiretroviral therapy. Additionally, TDF might be used in patients at risk of anemia. COMPETING INTEREST The authors have declared that no competing interests exist REFERENCE 1. MellorsJW, Munoz A, Giorgi JV.Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12); Egger M, May T, Chene G. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360(9327): Martin J, Volberding P. (2010). HIV and premature aging: a field still in its infancy. Annals of Internal Medicine; 153: World Health Organization. World Health Report on HIV/AIDS 2004, Mavigner M, Delobel P, Cazabat M, Dubois M. HIV-1 Residual Viremia Correlates with persistent T-cell activation in poor immunological responders to combination Antiretroviral therapy. PLos ONE2009: 4(10). e7658.doi: /journal.pone Kaufmann GR, Perrin L, Pantaleo G. CD4 T lymphocyte recovery in individuals with advance HIV-1 infection receiving potent ART for 4 years: the swiss HIV cohort study. Arch intern. Med. 2003;163 (18) Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19(6): Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ: Impact of viral hepatitis co- infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18(8): Akinola NO, Olasode O, Adediran IA, Onayemi O, Mu- rainah A, Irinoye O, et al. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substi- tute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis 2004; 39(4): Spacek LA, Griswold M, Quinn TC, Moore RD. Total lym- phocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in re- source-limited settings. AIDS 2003; 17(9): Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resourcelimited settings. AIDS 2003; 17(4): Barrios A, Garcia-Benayas T, Gozalez- Lahoz J, Soriano V. Teno- fovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18: Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5: Rodriguez-Novoa S, Labarga P, D Avolio A, Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: Deebii, N et al JMSCR Volume 03 Issue 10 October Page 7834
Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationThis is the author s version of a work that was submitted/accepted for publication in the following source:
This is the author s version of a work that was submitted/accepted for publication in the following source: Kelly, Mark D., Gibson, Abby, Bartlett, Harry, Rowling, Diane, & Patten, John (2013) Tenofovir-associated
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationSupplementary Appendix
Supplementary Appendix This supplementary Appendix accompanies the article Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings (Archives of Internal Medicine, September 22, 2008),
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationEffect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria
Niger J Paed 2014; 41 (1): 1-6 Ebonyi AO Oguche S Dablets E Sumi B Yakubu E Sagay AS ORIGINAL Effect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationAntiretroviral Therapy Cohort Collaboration
Antiretroviral Therapy Cohort Collaboration http://www.bristol.ac.uk/art-cc/research/presentations/ 2015 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 2015 Margaret
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationIs total lymphocyte count a predictor for CD4 cell count in initiation antiretroviral therapy in HIV-infected patients?
ORIGINAL ARTICLE Is total lymphocyte count a predictor for CD4 cell count in initiation antiretroviral therapy in HIV-infected patients? Alireza Abdollahi 1,2, Hana Saffar 2, Saeed Shoar 2, Siroos Jafari
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationJMSCR Vol 3 Issue 12 Page December 2015
www.jmscr.igmpublication.org Impact Factor 3.79 Index Copernicus Value: 5.88 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v3i12.45 Correlation of CD4 T Cell Count with Absolute
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationA Study on Estimated Glomerular Filtration Rate As A Predictor of Renal Dysfunction Among Adult Hiv Patients on Highly Active Antiretroviral Therapy
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 10 Ver. IX (Oct. 2017), PP 28-34 www.iosrjournals.org A Study on Estimated Glomerular Filtration
More information1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other
Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search
More informationTDF Renal Dysfunction
TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape
More informationObjective: Specific Aims:
Title: Retention to Care of HIV pregnant females in Kumasi, Ghana Brown Faculty: Aadia Rana, MD. Assistant Professor of Medicine in Division of Infectious Diseases, Awewura Kwara, Assistant Professor of
More informationInvestigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort A. Lacey 1, W. Tinago 1, E. Alvarez Barco 1, A.J. Macken
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationTotal lymphocyte count as a surrogate marker for CD4 count in resource-limited settings
Obirikorang et al. BMC Infectious Diseases 2012, 12:128 RESEARCH ARTICLE Open Access Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings Christian Obirikorang 1*, Lawrence
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationSupplementary Material. In this supplement we derive the full form of the monetary and health costs of testing
Supporting document Supplementary Material In this supplement we derive the full form of the monetary and health costs of testing every years, and ; we derive the approximation shown in (1); and we justify
More informationORIGINAL INVESTIGATION. CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study ORIGINAL INVESTIGATION Gilbert R. Kaufmann, MD; Luc
More informationLong-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral Therapy During Asymptomatic HIV-Infection
JAIDS Journal of Acquired Immune Deficiency Syndromes 27:266 271 2001 Lippincott Williams & Wilkins, Inc., Philadelphia Long-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:
More informationIntroduction: WHO recommends that criteria for starting ART be defined in national protocols and that these
ISSN: 0975-766X Available Online through Research Article www.ijptonline.com HEALTH PROFILE OF HIV POSITIVE INDIVIDUALS AT ANTI RETROVIRAL TREATMENT CENTRE, KADAPA DISTRICT Dr.K.Chandra Sekhar *, Dr. K.J.Kishore
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationInt. J. Adv. Res. Biol. Sci. (2017). 4(8): 28-35
Int. J. Adv. Res. Biol. Sci. (1). (8): 835 International Journal of Advanced Research in Biological Sciences ISSN: 38869 www.ijarbs.com DOI: 1.19/ijarbs Coden: IJARQG(USA) Volume, Issue 8 1 Research Article
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationAntiviral Therapy 13:
Antiviral Therapy 13:1091 1095 Short communication Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients Stefan Mauss
More informationIschemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division
More informationIncomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
MAJOR ARTICLE HIV/AIDS Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment Colleen F. Kelley, 1,a Christina M. R. Kitchen, 2,a Peter
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationAdherence to antiretroviral drugs among AIDS patients in Sagamu, Nigeria
International Journal of Biomedical and Health Sciences 094-44/200 $12.00 + 0.00 Vol. 4, No. 2, June 0, 200 200 African Studies on Population and Health Printed in Nigeria http://www.asopah.org IJBHS 20009/4201
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationImpact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients
CLINICAL SCIENCE Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients Michael Horberg, MD,* Beth Tang, MA, William Towner, MD, Michael Silverberg, PhD,* Susan Bersoff-Matcha,
More informationTitle: What ARV regimen to start in children 3 years old? (TDF)
Title: What ARV regimen to start in children 3 years old? (TDF) Contents 1. PICO question... 1 2. Search strategy... 1 3. Flow diagram of screening process... 2 4. Evidence summaries... 2 5. Bibliography
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus Infected Cohort
More informationOCCURRENCE OF PNEUMOCYSTIS PNEUMONIA IN HIV-INFECTED PATIENTS AND THE INTERFERENCE OF THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Received: August 24, 2007 Accepted: December 6, 2007 Abstract published online: December 17, 2007 Full paper published online: March 8, 2008 J. Venom. Anim. Toxins incl. Trop. Dis. V.14, n.1, p.152-160,
More informationThe role of a Pharmacist in the analysis of adherence rates and associated factors in HIV-patients registered on Centralized Chronic Medicines
The role of a Pharmacist in the analysis of adherence rates and associated factors in HIV-patients registered on Centralized Chronic Medicines Dispensing and Distribution (CCMDD) programme in the public
More informationChapter 8. Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates
Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates Nienke Vrisekoop *1, Belete Tegbaru *1,2, Margreet Westerlaken 1, Dawit Wolday
More informationDate of study period: April 12 May 7, 2010 and August September, 2010
Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationAssessment of the therapeutic success of antiretroviral combinations used in a HIV treatment center, Jos, Nigeria
World Journal of Pharmaceutical Sciences ISSN (Print): 3-330; ISSN (Online): 3-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original Article
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationRole of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash
Review Article Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 89 Role of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash Weerawat Manosuthi,
More informationPredicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings
Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings By James Nugent A Master s Paper submitted to the faculty
More informationEfficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens
O_05 Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens Linda Aurpibul MD. 1, Thition Narkbunnam MD. 2,
More informationAnna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma
Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma Research & Early Discovery Funding: Wellcome Trust, National
More informationThe monitoring of HIV-infected patients is based on
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 32, Number 6, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/aid.2015.0348 Prognostic Value of HIV-1 RNA on CD4 Trajectories and Disease Progression Among Antiretroviral-Naive
More informationA Control Theoretic Approach to HIV/AIDS Drug Dosage Design and Timing the Initiation of Therapy
A Control Theoretic Approach to HIV/AIDS Drug Dosage Design and Timing the Initiation of Therapy by Annah Mandu Jeffrey Submitted in partial fulfillment of the requirements for the degree Philosophae Doctoral
More informationEmtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationPlasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study
Kunimoto et al. Journal of Pharmaceutical Health Care and Sciences (2016) 2:22 DOI 10.1186/s40780-016-0056-5 RESEARCH ARTICLE Open Access Plasma tenofovir trough concentrations are associated with renal
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3
VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationResults. Materials and Methods
Original Research Efficacy of total lymphocyte count as a surrogate for CD4 cell counts in HIV-infected adults in the era of higher treatment cutoffs and less funding: a cross-sectional study Mwenda V
More informationMariza Vono Tancredi. Eliseu Alves Waldman
Mariza Vono Tancredi Eliseu Alves Waldman RATIONALE The clinical and laboratorial data from a population at a STD/AIDS Referral and Training Center (CRT) in Sao Paulo, Brazil, with 7,853 HIV infected individuals
More informationIntermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Intermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption Joseph L. Yozviak DO,
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationJMSCR Vol 4 Issue 07 Page July 2016
earliest reports of kidney disease in HIV infection were published in the 1980s; retrospectively, these subsequently became recognized as HIVwww.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationHIV-HBV coinfection: Issues with treatment in 2018
HIV-HBV coinfection: Issues with treatment in 2018 Pr Karine Lacombe, INSERM UMR-S1136, IPLESP Infectious Diseases Dpt, St Antoine, AP-HP Sorbonne Université, Paris, France Global epidemiology Same routes
More informationSimbarashe Takuva, 1 Mhairi Maskew, 2 Alana T. Brennan, 3 Ian Sanne, 1,2 A. Patrick MacPhail, 1,2 and Mathew P. Fox 2,3,4. 1.
Tropical Medicine Volume 2013, Article ID 162950, 6 pages http://dx.doi.org/10.1155/2013/162950 Clinical Study Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationDepartment of Medical Laboratory Sciences, Addis Ababa University, Ethiopia. Department of Medical Biochemistry, Addis Ababa University, Ethiopia
Prevalence of Anemia Before and After Initiation of Antiretroviral Therapy on HIV Infected Patients at Ras Desta Damtew Memorial Hospital, Addis Ababa, Ethiopia Aster Tsegaye 1, Kassu Desta 1, Dessiet
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationDEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.
2013 Consolidated ARV Guidelines H I V / A I D S Treatment Recommendations for DEPARTMENT Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer Objectives of Presentation obackground ooverview
More informationPatients with persistently low CD4 counts on antiretroviral
Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV
More informationPrevalent opportunistic infections associated with HIV-positive children 0-5 years in Benin city, Nigeria
Malaysian Journal of Microbiology, Vol 4(2) 2008, pp. 11-14 http://dx.doi.org/10.21161/mjm.11508 Prevalent opportunistic infections associated with HIV-positive children 0-5 years in Benin city, Nigeria
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationEarly Antiretroviral Therapy
Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More information